Farzad E, Holton D, Long R, FitzGerald M, Laszlo A, Njoo H, Fanning A, Hershfield E, Hoeppner V, Allen E
Division of Blood Borne Pathogens, LCDC, Ottawa.
Can J Public Health. 2000 Sep-Oct;91(5):366-70. doi: 10.1007/BF03404809.
To estimate the prevalence of resistance of Mycobacterium tuberculosis to first-line antituberculosis drugs in Canada.
M. tuberculosis isolates from one third of all culture-positive tuberculosis (TB) cases diagnosed between February 1, 1993 to January 31, 1994 in Canada were collected prospectively. Proportion of drug-resistant isolates and the factors related to drug resistance were measured.
Of 458 study cases, 40 (8.7%) had resistance to at least one first-line antituberculosis drug, of which 5.9% had mono-resistance, 0.7% had multidrug-resistance(MDR-TB)--i.e., resistance to at least isoniazid and rifampin--and 2.2% had other patterns. The overall prevalence of resistance among the foreign-born cases was 10.6% with the highest level among those who resided in Canada for less than four years (15.5%).
Canada has a relatively low prevalence of antituberculosis drug resistance and a very low prevalence of MDR-TB. Some new immigrants to Canada may be at higher risk for drug resistance and their initial treatment needs to be tailored accordingly.
评估加拿大结核分枝杆菌对一线抗结核药物的耐药率。
前瞻性收集1993年2月1日至1994年1月31日期间在加拿大诊断出的所有培养阳性结核病（TB）病例中三分之一的结核分枝杆菌分离株。测定耐药分离株的比例以及与耐药相关的因素。
在458例研究病例中，40例（8.7%）对至少一种一线抗结核药物耐药，其中5.9%为单耐药，0.7%为耐多药（MDR-TB），即至少对异烟肼和利福平耐药，2.2%为其他耐药模式。外国出生病例的总体耐药率为10.6%，在加拿大居住不到四年的人群中耐药率最高（15.5%）。
加拿大抗结核药物耐药率相对较低，耐多药结核病患病率极低。一些加拿大新移民可能耐药风险较高，需要据此调整其初始治疗方案。
